SCHEMBL19684906

SCHEMBL19684906

Cc1ccc2c(c1OCc1ccccc1)C(=O)N[C@@H](C)CO2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.41
POLB P06746 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
CREBBP Q92793 4/20 0.37
BRD4 O60885 3/20 0.37
HTR1D P28221 1/20 0.36
HTR1B P28222 1/20 0.36
MAOB P27338 4/20 0.36
MAOA P21397 2/20 0.36
FFAR1 O14842 2/20 0.36
PTGER4 P35408 3/20 0.35
PTGER3 P43115 3/20 0.35
PTGER2 P43116 3/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
NPC1 O15118 1/20 0.35
NFKB1 P19838 1/20 0.35
GRM5 P41594 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19667140 0.81 CREBBP (0.48) POLBCREBBPBRD4MAOBMAOA
SCHEMBL19667141 0.81 CREBBP (0.48) POLBCREBBPBRD4MAOBMAOA
SCHEMBL19684910 0.72 KLK7 (0.39) PTPN1FFAR1PTGER4PTGER3PTGER2
SCHEMBL13802178 0.72 HTR2A (0.41) LMNACREBBPALDH1A1HPGDKMT2A
SCHEMBL13801962 0.72 HTR2A (0.41) LMNACREBBPALDH1A1HPGDKMT2A
SCHEMBL13802074 0.68 LMNA (0.43) PTPN1LMNAMAOBFFAR1
SCHEMBL19684909 0.66 KLK7 (0.41) PTPN1FFAR1PTGER4PTGER3PTGER2
SCHEMBL19684903 0.66 PTK2 (0.37) POLBLMNAALDH1A1
SCHEMBL12749327 0.66 TSHR (0.34) CREBBPKMT2AMEN1
SCHEMBL13802107 0.65 MAOB (0.43) MAOBFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10220037-B2 Substituted carbonucleoside derivatives useful as anticancer agents PFIZER INC. (US) 2019-03-05 US disclosed
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2017-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS DUT, NCL, TYMP PTPN1 4606/4885POLB 91/4885LMNA 452/4885
US-10220037-B2 Substituted carbonucleoside derivatives useful as anticancer agents DUT, NCL, TYMP PTPN1 4606/4885POLB 91/4885LMNA 452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.